Projects per year
Personal profile
Biography
A/Prof David Pook is a Medical Oncologist who performs clinical research through the School of Clinical Sciences and translational research with the Prostate Cancer Research Program in the Department of Anatomy and Developmental Biology. A/Prof Pook's research work is directed towards the identification and testing of novel agents in genitourinary cancers.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Medicine, FRACP, Royal Australasian College of Physicians (RACP)
Medical Oncology, MD, University of Melbourne
Medical Science, BMedSci, University of Tasmania
Medicine, MBBS (Hons), University of Tasmania
External positions
Medical Oncologist, Monash Health
2010 → …
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP
Stockler, M. R., Martin, A. J., Davis, I. D., Dhillon, H. M., Begbie, S. D., Chi, K. N., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W. E., Horvath, L. G., Joshua, A. M., Lawrence, N. J., Marx, G. M., McCaffrey, J., McDermott, R., McJannett, M., North, S. A., Parnis, F., Parulekar, W. R., & 14 others, 10 Mar 2022, In: Journal of Clinical Oncology. 40, 8, p. 837-846 10 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access13 Citations (Scopus) -
Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer
Porter, L. H., Bakshi, A., Pook, D., Clark, A., Clouston, D., Kourambas, J., MURAL investigators, Goode, D. L., Risbridger, G. P., Taylor, R. A. & Lawrence, M. G., Jun 2021, In: Journal of Pathology. 254, 2, p. 121-134 14 p.Research output: Contribution to journal › Article › Research › peer-review
9 Citations (Scopus) -
CX-5461 sensitizes DNA damage repair-proficient castrate-resistant prostate cancer to PARP inhibition
Lawrence, M. G., Porter, L. H., Choo, N., Pook, D., Grummet, J. P., Pezaro, C. J., Sandhu, S., Ramm, S., Luu, J., Bakshi, A., Goode, D. L., Sanij, E., Pearson, R. B., Hannan, R. D., Simpson, K. J., Taylor, R. A., Risbridger, G. P. & Furic, L., Nov 2021, In: Molecular Cancer Therapeutics. 20, 11, p. 2140-2150 11 p.Research output: Contribution to journal › Article › Research › peer-review
6 Citations (Scopus) -
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Choueiri, T. K., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Zurawski, B., Juárez, V. M. O., Hsieh, J. J., Basso, U., Shah, A. Y., Suárez, C., Hamzaj, A., Goh, J. C., Barrios, C., Richardet, M., Porta, C., Kowalyszyn, R., Feregrino, J. P., Zolnierek, J., Pook, D., & 12 others, 4 Mar 2021, In: The New England Journal of Medicine. 384, 9, p. 829-841 13 p.Research output: Contribution to journal › Article › Research › peer-review
607 Citations (Scopus) -
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy
Sweeney, C. J., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W. E., Horvath, L. G., Joshua, A. M., Lawrence, N. J., Marx, G. M., McCaffrey, J., McDermott, R., McJannett, M., North, S. A., Parnis, F., Parulekar, W., Pook, D. W., & 13 others, Sep 2021, In: European Urology. 80, 3, p. 275-279 5 p.Research output: Contribution to journal › Article › Research › peer-review
18 Citations (Scopus)